GLP-1 compounding
The next GLP-1 enforcement story is less about one headline and more about a live control file: shortage status, patient-specific need, dosing, pharmacy identity, API origin, and shipping conditions.
GLP-1 compounding has moved from a shortage-era workaround into a tighter enforcement lane. FDA still recognizes that compounding can serve a real patient need when an approved drug cannot meet that need, or when an approved drug is not commercially available. FDA also says compounded drugs are not FDA-approved and do not go through FDA review for safety, effectiveness, or quality before they reach patients.
That distinction makes GLP-1 compounding a durable monitoring topic for pharmacies, telehealth clinics, weight-loss platforms, supplier-quality teams, and the vendors who support them. Demand remains high. The public record keeps changing. FDA has already identified problems that point to specific operational controls.
FDA's shortage guidance explains why timing matters. When an FDA-approved drug appears on FDA's drug shortages list, some restrictions on compounding drugs that are essentially copies of approved drugs may not apply. Other legal conditions still apply. For 503A pharmacies, FDA points to patient-specific prescriptions and limits on compounding copies in regular or inordinate amounts. For 503B outsourcing facilities, FDA says new orders after a drug leaves the shortage list can trigger enforcement risk, with a limited policy for certain orders received while the drug was still in shortage.
Teams should treat shortage status as a change-control input, not a background fact. A GLP-1 program that looked defensible during a shortage can become riskier when the shortage listing changes, especially if marketing pages, intake flows, formularies, or pharmacy instructions keep moving as if nothing changed.
FDA's GLP-1 concern page names several risk areas that show up before a formal enforcement action. The agency has cited dosing errors tied to compounded injectable semaglutide, including reports involving hospitalization. FDA has also flagged compounded semaglutide or tirzepatide prescriptions that go beyond the dosing or titration schedule in the approved drug labeling.
That creates a practical file check for clinics and pharmacies: can the patient, prescriber, and pharmacy understand the same dose, concentration, syringe volume, and titration schedule? If the answer depends on a verbal explanation or a conversion chart that lives outside the patient record, the control is thin.
FDA says injectable GLP-1 drugs require refrigeration as described in their package inserts. The agency has received complaints that some compounded GLP-1 products arrived warm or with inadequate ice packs. For sterile injectables, cold-chain handling sits close to product quality. FDA recommends patients not use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration.
FDA has also described fraudulent compounded semaglutide and tirzepatide products marketed in the United States. Some labels allegedly used the name of a licensed pharmacy that, based on FDA's information, did not compound the product. Other labels named pharmacies that did not exist.
For buyers and compliance teams, those two points belong together. A label should identify a real pharmacy that can verify the product. The shipping record should show the product stayed within the required handling conditions. A patient complaint about warm product should trigger more than customer-service routing.
FDA has also put GLP-1 active pharmaceutical ingredients under border scrutiny. The agency says Import Alert 66-80 includes a Green List for certain GLP-1 APIs and is meant to help stop APIs with potential quality concerns from entering the U.S. supply chain. FDA says the import alert does not block legal importation of GLP-1 APIs from compliant API manufacturers.
A recent company example shows why the upstream record matters. FDA's warning letter to Harbin Jixianglong Biotech Co., Ltd. discusses semaglutide API traceability, supplier qualification, relabeling, repackaging, batch information, retest-date records, and import-alert status. FDA said it was concerned that relabeling may have circumvented import-alert safeguards.
That is a supplier-quality issue as much as a GLP-1 issue. The receiving team should be able to prove who manufactured the API, who relabeled or repackaged it, which batch records support the material, and whether the import path matches the underlying facility status.
FDA's February 2026 warning-letter group to GLP-1 telehealth and compounding businesses, including Kare Solutions, LLC dba Zappy, showed how public-facing claims and commercial pathways can become part of the enforcement record. FDA Warning Monitor previously covered that group in its article on FDA's GLP-1 compounding crackdown, and the supplier side in its article on GLP-1 API traceability.
The useful read is not “FDA dislikes GLP-1 compounding.” FDA's own materials leave room for lawful compounding when the facts support it. The better read is that FDA expects the record to line up across the whole route: shortage status, patient need, prescribing, pharmacy identity, product labeling, API source, storage, adverse-event handling, and public claims.
For GLP-1 compounders, telehealth operators, clinics, consultants, and compliance vendors, the weekly watchlist should include FDA shortage changes, warning letters, import alerts, recall records, adverse-event language, and any FDA update to its unapproved GLP-1 page. Teams should also watch their own public pages and checkout flows, because FDA warning letters often quote the public web record.
The value is not panic. The value is finding the source-linked change while there is still time to tighten records, update scripts, ask a supplier for proof, or stop a weak claim from becoming part of a public letter.
Prefer LinkedIn? Follow FDA Warning Monitor for public warning-letter, recall, and enforcement signals.
FDA: Concerns with unapproved GLP-1 drugs used for weight loss
FDA: Compounding when drugs are on FDA's drug shortages list
FDA: Compounding and the FDA, questions and answers
FDA Import Alert 66-80 Green List for GLP-1 APIs
FDA warning letter: Harbin Jixianglong Biotech Co., Ltd.
FDA warning letter: Kare Solutions, LLC dba Zappy